Germany: Lonza agrees to acquire Merck’s US CDMO business, expanding its footprint to nine sites
Lonza, a Swiss CDMO, will acquire Merck KGaA's US CDMO business for low- to mid-triple-digit millions of Swiss francs. The deal expands Lonza's US sites from 4 to 9 and adds 1,100 employees. Merck retains its BioReliance Contract Testing Services. Lonza expects CHF 250m in sales from the acquired sites by 2028, with minimal group impact. The transaction is cash-funded and maintains Lonza's BBB+ rating.
How this was made
The 30-second read
Why it matters
The deal adds ~CHF 250m in sales by 2028 and expands Lonza's US footprint, potentially enhancing its market position and share price.
Market read
First disclosure of a mid-sized M&A in the biotech manufacturing sector, likely to affect Lonza's valuation and peer dynamics.
What to watch
Regulatory approvals and cultural integration of the acquired sites may delay expected benefits.
Background
Lonza, a Swiss CDMO, is expanding its US operations by acquiring Merck KGaA's US CDMO business, which includes five sites and 1,100 employees.
Market effects
Strengthens the US CDMO sector, may pressure peers to consolidate or expand.
Boosts the biotech manufacturing landscape in the United States.
Highlights continued consolidation in global contract manufacturing services.
Counterpoint
Integration risks and potential overpayment could weigh on Lonza if synergies fall short.
Key entities
- CompanyLonza Group AG
Swiss-based contract development and manufacturing organization acquiring the US CDMO business.
- CompanyMerck KGaA
German science and technology company selling its US CDMO business.
